Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
156.01
+0.45 (0.29%)
Jul 3, 2025, 1:00 PM - Market closed
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
4.20
Revenue / Employee
$646,857
Employees
138,100
Market Cap
375.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
Thermo Fisher Scientific | 42.90B |
JNJ News
- 1 day ago - Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations - GlobeNewsWire
- 4 days ago - Johnson & Johnson: Patience Will Be Rewarded - Seeking Alpha
- 4 days ago - This Changes Everything: One Of The Most Important Shifts For Dividend Investors - Seeking Alpha
- 10 days ago - Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential - Seeking Alpha
- 10 days ago - How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years - Seeking Alpha
- 10 days ago - Best Dividend Kings: June 2025 - Seeking Alpha
- 11 days ago - IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) - PRNewsWire
- 14 days ago - If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global Diversification - Seeking Alpha